


Open Access Article

 <https://doi.org/10.55463/issn.1674-2974.49.12.11>

Effects of Humectants and Oleogeneous Base in the Photostabilization of Secnidazole Emulgels

Sidrah Hassan¹, Hina Abrar², Mirza Tasawer Baig¹, Hina Yasin², Kaneez Fatima³, Hira Naeem⁴,
Affan Ali⁵, Kiran Qadeer³, Kishan Das⁵, Ayaz Ali Khan⁶, Adeel Arsalan¹

¹ Faculty of Pharmacy, Ziauddin University, Link Road, Education City, Eastern Bypass, Malir, Karachi, Pakistan

² Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan

³ Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan

⁴ Baqai Institute of Pharmaceutical Sciences, Baqai Medical University, Karachi, Pakistan

⁵ Drug Regulatory Authority of Pakistan, Karachi, Pakistan

⁶ School of Pharmacy, University of Management and Technology, Lahore, Pakistan

Received: August 17, 2022 / Revised: October 12, 2022 / Accepted: November 10, 2022 / Published: December 30, 2022

Abstract: This investigation aims to study the formulation of emulgel preparations of secnidazole (SZ). The variables in the composition of the oleaginous phase (liquid paraffin and castor oil) and humectants (propylene glycol and glycerol) and the physical and rheological properties like homogeneity, spreadability, and extrudability were studied. Variations in the viscosity of SZ emulgels were observed due to changes in formulations. The viscosity was central to the stability of the SZ emulgel preparations. SZ is a photosensitive drug, and irradiation formed its primary photodegraded product 2,4-(N-2-hydroxypropyl) diaza-3-methyl-1-nitro-1,5-dione. SZ has been subjected to photolysis by irradiation, and the clear first-order rate constant, k_{obs} , for the degradation of SZ has been determined. The values of k_{obs} ($2.79-5.12 \times 10^{-2} \text{ min}^{-1}$) have decreased with the increase in viscosity (20085-29985 cP) of emulgel preparations. The ratio of stabilization is in the range of 2.31-4.22. It is concluded that increasing the viscosity of pharmaceutical preparations may enhance the photostability of light-sensitive drugs.

Keywords: secnidazole, emulgel, viscosity, kinetics, photostabilization.

保湿剂和油性碱对塞克硝唑乳胶光稳定作用的影响

摘要: 本研究旨在研究塞克硝唑乳膠製劑的配方。研究了含油相 (液體石蠟和蓖麻油) 和保濕劑 (丙二醇和甘油) 的組成變量以及均勻性、鋪展性和可擠出性等物理和流變特性。由於配方的變化, 觀察到塞克硝唑乳膠粘度的變化。粘度對塞克硝唑乳膠製劑的穩定性至關重要。塞克硝唑是一種光敏性藥物, 輻照形成其主要光降解產物 2,4-(N-2-羥丙基) 迪亞扎-3-甲基-1-硝基-1,5-二酮。塞克硝唑已通過輻照進行光解, 並確定了塞克硝唑降解的明確一級速率常數球棒。球棒 ($2.79-5.12 \times 10^{-2} \text{ 分鐘}^{-1}$) 的值隨著乳膠製劑粘度 (20085-29985 厘泊) 的增加而降低。穩定比在 2.31-4.22 範圍內。結論是增加藥物製劑的粘度可能會增強光敏藥物的

光穩定性。

关键词：塞克硝唑，乳膠，粘度，動力學，光穩定。

1. Introduction

Emulgel is one of the most appealing semisolid dosage forms. It has dual controlled release systems like emulgels and emulsions, which are directly applied at the site of action and produce an extended period of action at the site of application [1]. The use of high molecular weight polymers like hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, carboxymethyl cellulose, carbopol 940, carbopol 934 and xanthine gum are usually preferred as gelling agents. Castor oil, liquid paraffin, clove oil, sesame oil, soybean oil are mainly used for the oleaginous phase and penetration enhancers in semisolid preparations [2]. Glycerin, polyethylene glycol, propylene glycol and ethylene glycol are used as humectant, to keep the preparation moist [3]. The formulation possesses high viscosity, spreadability, homogeneity with filming abilities at low concentrations of polymers [4].

Secnidazole (SZ) (an anti-infective) (Fig. 1) belongs to the nitroimidazole. It is chemically known as (RS)-1-(2-methyl-5-nitroimidazole-1yl) propane-2-ol [5]. SZ is sparingly soluble in water [6]. It is used for treating amebiasis, giardiasis, trichomoniasis, and bacterial vaginosis. SZ is a broad spectrum antibiotic and possesses efficacy against protozoa [7]. UV-visible spectrophotometer was by many researchers for the quantitative and qualitative analysis of SZ [8-11]. The major advantage of this technique is to provide rapid result, high selectivity, accuracy, precision, and sensitivity with the degradation products of drugs [12, 13]. The major suitability of UV-visible spectrometry is the rapid quantitative analysis of pure SZ and its degradation [14].




Fig. 1 Chemical structure of SZ

The main objective of this investigation was to formulate a stable SZ emulgel. Moreover, the stability-like photostability was also carried out for the assay of SZ in emulgel formulations and in aqueous preparations. However, the effect of different oleaginous phases and humectants on the stability of SZ in emulgel is still not determined. The work

includes the rate constant of photolysis (kobs) of pure SZ solution (5×10^{-5} M) at different pH acidic (4.0), neutral (7.0) and alkaline (9.0).

2. Materials and Methods

2.1. Materials

Secnidazole (SZ) (98%) was gifted from Nabi-Qasim Industries Private Limited, Karachi, Pakistan with assigned purity. Carbopol 934 used as the gelling agent, mineral oil, castor oil, glycerol (85%), propylene glycol ($\geq 99\%$), citric acid (monohydrate), sodium citrate dehydrates, methanol, hydrochloric acid (HCl), potassium chloride (KCl), potassium hydroxide (KOH), sodium hydroxide (NaOH), methylparaben sodium (MP), and propylparaben sodium (PP) were purchased from Merck & Co. Whitehouse Station, NJ, USA. The SZ solutions and emulgels were prepared using freshly boiled de-ionized water.

2.2. SZ Emulgel Formulations

Carbopol 934 was selected as the gelling agent to prepare the gel matrix formulation [15]. Carbopol 934 was dispersed in hot distilled water with continuous stirring and adds methylparaben and propylparaben, then allowed to cool overnight. SZ (1% w/w) was added to the gel preparation and add glycerol and propyleneglycol to SZ gel.

Castor oil and liquid paraffin (mineral oil) were used as an oleaginous phase for SZ emulgel formulations. The oleaginous phase (castor oil or liquid paraffin) was added in SZ gel preparations to prepare (w/o) emulgel. Finally, a homogenizer homogenized the emulgels. The pH of the formulation was adjusted with citric acid buffer. The formulation and role of ingredients in SZ emulgel in this study are given in Table 1.

Table 1 Ingredients of formulations of SZ emulgel

Ingredients	% w/w	Role of Ingredients
Secnidazole	1	Active pharmaceutical ingredient
Carbopol 934	2.5	Gelling agent
Mineral oil and castor oil	5-7.5	Oleaginous phase
Glycerol, and propylene glycol	5-7.5	Humectant
Salt of methylparabens and propyl parabens	0.2 and 0.04	Preservative (antimicrobial)
Citric acid	0.3	Antioxidant/ Buffer
Sodium citrate dehydrate	0.6	Buffer
De-ionized water	Q.S	Vehicle

2.3. Measurements of pH

A digital pH meter with a glass electrode (model CP501; sensitivity 0.01 pH units, Emlenton, Poland) measured the pH of the emulgel formulations. Buffer tablets of pH = 4.0, 7.0 and 9.0 standardized the pH meter. The pH electrode was immersed directly in the emulgel to determine the pH adjusted to pH = 5.0.

2.4. Rheological Properties of SZ Emulgels

The effect of the oleaginous phase (castor oil and mineral oil) and humectants (glycerol and propylene) on the rheological properties like viscosity, homogeneity, spreadability, extrudability, physical appearance and of SZ emulgel were assayed.

2.5. Viscosity Measurements

The viscosity of SZ formulated emulgels were assayed by rotational viscometer (Brookfield Engineering Laboratories Inc. (Model LVDV-E., USA). The different formulations of SZ emulgel were taken in a 250 ml beaker and its pivot was dipped into the emulgel. The viscosity of the emulgel was analyzed by a spindle number 5 for 1 min at 25°C at different angular speeds and measured 3 times to exclude the variability and determine the mean viscosity [16].

2.6. Physical Appearance

The physical stability-like change in color, homogeneity and consistency and phase separation of SZ emulgel were visually observed.

2.7. Spreadability Test

The spreadability was determined by the wooden block and glass slide method. In this apparatus, emulgel present between 2 slides with a certain load, when the upper movable slide separates completely from the fixed slide time noted [1].

$$S = \frac{\text{Weight} \times \text{Length of slide}}{\text{Time taken for complete separation}} \times 100 \quad (1)$$

2.8. Extrudability Test (Tube Test)

The extrudability test is a primary test to determine the pressure force required to extrude the emulgel from a collapsible aluminum tube. It can be determined by the weight required to extrude 0.5 cm ribbon of emulgel in 10 sec. from the lacquered packaging tube.

2.9. Light Intensity Measurements

Potassium ferrioxalate actinometry was used to investigate the intensity of the irradiation source and a value of $1.20 \pm 0.11 \times 10^{17}$ quanta s^{-1} was obtained previously by [17].

2.10. Photolysis of SZ

1 g of different formulations of SZ emulgel was uniformly placed on 5 small glass slabs. These slabs

occurred at a distance of 30 cm in a dark chamber with a constant temperature and humidity ($25 \pm 2^\circ\text{C}/60\% \text{ RH}$) and illuminated by a Philips HPLN 125-W high-pressure mercury vapor fluorescent lamp. After 30 min of light exposure, each sample of emulgels was removed for the qualitative and quantitative estimation.

2.11. Thin Layer Chromatography

The photosensitizer preparations of SZ emulgels were extracted with KOH (0.1 M) with methanol (10:90 v/v) and subjected to TLC using precoated silica emulgel 60 F 254 as the stationary phase (E. Merck). This helps in the determination of SZ and its photodegraded product. The spots were determined under UV light (209 nm) [18].

2.12. Accelerated Stability Studies

The formulated SZ emulgels were packed and sealed in aluminum tubes. These tubes are placed at $40 \pm 2^\circ\text{C}/5\% \pm 5\% \text{ RH}$ for 3 months in the stability chamber. The withdrawn samples were pH, physical appearance, SZ content and their rheological properties were evaluated every 15 days.

2.13. Assay of SZ

A UV spectrometric method was used to assay SZ in aqueous solution and in different emulgel formulations. The measurements of absorbance and spectra were assayed on a Shimadzu UV-visible spectrometer (UV-1800), using matched quartz cells of 10 mm in path length. The baseline was corrected before assay by the built-in baseline memory at the initializing period with an auto-zero adjustment by a one-touch operation.

The pure SZ solution and different formulations of SZ emulgel weighed 1g was diluted in 50 ml of HCl-KCl buffer (0.001 N) solution (pH=2.0) and poured in a 250 ml separating funnel. Chloroform was added in the funnel and vigorously shaken for extracting lipid components. The aqueous extracted layer of SZ was separated and added to KOH (0.1 N) at pH=9.0 for the quantitative and qualitative assay of SZ by UV-visible spectrometry. The same process was repeated with photolyzed aqueous preparation and emulgel formulations of SZ for the qualitative and quantitative assay of SZ and its photodegraded product (2,4-(N-2-hydroxypropyl) diaza-3-methyl-1-nitro-1,5-dione,

3. Results

3.1. Formulation of SZ Emulgel

The formulation composition of SZ (1%, w/w) emulgel is given in Table 2. The quantities of carbopol, methylparaben and propylparaben, citrate buffer were used as constant. In this study, the effect of mineral oil and castor oil as an oleaginous phase and glycerol and propylene glycol used as humectants in the

formulation of emulgel preparation. The change in formulations was used to determine the stability of SZ in emulgel preparations (Table 2).

Table 2 Formulation composition of SZ emulgel*

Formulations	SZ (1% w/w)	CP-934 Gel	LP	CO	PG	GL	MP	PP	Citrate Buffer
Pure SZ	-	-	-	-	-	-	-	-	-
EG 01	1	48	4.48	-	6.25	-	0.2	0.04	0.6
EG 02	1	48	6.25	-	8.02	-	0.2	0.04	0.6
EG 03	1	48	6.25	-	4.48	-	0.2	0.04	0.6
EG 04	1	48	7.50	-	5.00	-	0.2	0.04	0.6
EG 05	1	48	8.02	-	6.25	-	0.2	0.04	0.6
EG 06	1	48	5.00	-	7.50	-	0.2	0.04	0.6
EG 07	1	48	5.00	-	5.00	-	0.2	0.04	0.6
EG 08	1	48	7.50	-	7.50	-	0.2	0.04	0.6
EG 09	1	48	6.25	-	6.25	6.25	0.2	0.04	0.6
EG 10	1	48	-	4.48	-	6.25	0.2	0.04	0.6
EG 11	1	48	-	6.25	-	8.02	0.2	0.04	0.6
EG 12	1	48	-	6.25	-	4.48	0.2	0.04	0.6
EG 13	1	48	-	7.50	-	5	0.2	0.04	0.6
EG 14	1	48	-	8.02	-	6.25	0.2	0.04	0.6
EG 15	1	48	-	5.00	-	7.5	0.2	0.04	0.6
EG 16	1	48	-	5.00	-	5	0.2	0.04	0.6
EG 17	1	48	-	7.50	-	7.5	0.2	0.04	0.6
EG 18	1	48	-	6.25	-	6.25	0.2	0.04	0.6

* QS to produce 100 g by water † CP-934 (Carbopol-934); LP (liquid paraffin); PG (propyleneglycol); GL (glycerol); MP (methylparaben); PP (propylparaben)

3.2. Rheological Properties of SZ Emulgels

The rheological parameters like spreadability, extrudability, viscosity, physical appearance of the different formulations of SZ emulgels have been evaluated (Table 3).

Table 3 Viscosity, spreadability and extrudability of SZ emulgel preparation

Emulgel Code	Viscosity (cp)	Spreadability (cm/sec)	Extrudability
EG 01	23955	5.9	+++
EG 02	21395	4.2	++
EG 03	22085	4.9	++
EG 04	21038	3.9	+
EG 05	20385	3.8	+
EG 06	21345	4.1	++
EG 07	21987	4.6	++
EG 08	20085	3.6	+
EG 09	21325	4.0	+
EG 10	29985	9.2	+++
EG 11	28330	7.5	+++
EG 12	29380	8.5	+++
EG 13	28214	7.3	+++
EG 14	28753	7.9	+++
EG 15	28444	7.7	+++
EG 16	29242	8.3	+++
EG 17	28000	7.1	+++
EG 18	26989	6.4	+++

3.3. Photodegradation of SZ

Light mainly influences the rate of photolysis of the photolabile drugs [19]. SZ is sensitive to light and photolyzed in the presence of visible and UV light [20]. The UV irradiation has high energy content, thus, increases the photolytic degradation of SZ. The different concentrations of oleaginous phase and humectants may affect the clear first-order rate constant (k_{obs}) for the photolysis of SZ in emulgel formulations compared to aqueous preparation (Table 4).

Table 4 Clear first-order rate constant (k_{obs}) for the photolysis of SZ and stabilization ratio*

Emulgel Code	$k_{obs} \times 10^2 \text{ (min}^{-1}) \pm \text{SD}$	t_{90} (~min)	Stabilization Ratio
Pure Solution	11.81 ± 0.008	8.89	-
EG 01	3.90 ± 0.012	26.92	3.03
EG 02	4.21 ± 0.017	25.00	2.81
EG 03	4.05 ± 0.013	26.25	2.95
EG 04	4.41 ± 0.019	23.86	2.68
EG 05	4.49 ± 0.018	23.34	2.63
EG 06	4.19 ± 0.015	25.06	2.82
EG 07	4.15 ± 0.011	25.31	2.85
EG 08	5.12 ± 0.017	20.51	2.31
EG 09	4.18 ± 0.017	25.12	2.83
EG 10	2.79 ± 0.014	37.50	4.22
EG 11	3.55 ± 0.012	29.58	3.33
EG 12	2.99 ± 0.011	35.12	3.95
EG 13	3.72 ± 0.013	28.38	3.19
EG 14	3.33 ± 0.013	31.53	3.55
EG 15	3.45 ± 0.010	30.43	3.42
EG 16	3.08 ± 0.012	33.87	3.81
EG 17	3.61 ± 0.009	29.08	3.27
EG 18	3.83 ± 0.012	27.63	3.11

* The value of k_{obs} for the photodegradation of SZ in aqueous solution

3.4. Analysis of SZ and Its Photoproducts

A standard curve of absorbance against the concentration of SZ within the range 0.5-5.0 M × 10⁻⁵ has formed a linearity with least-squares regression equation ($R^2 = 0.998$) (Fig. 2). The peak (λ_{max}) of pure SZ solution has been observed in spectra at 311 (a), 320 (b), 277 (c) and 313 nm in neutral pH (7.0), alkaline (KOH, 9.0), acidic (HCl, 4.0) and alkaline methanol (KOH, 9.0) pH (Fig. 3). The light was exposed to pure SZ solution and different formulations of SZ emulgel at a time interval of 30 min for 150 min. A constant loss was in the peak of SZ in pure aqueous solution and emulgel formulations in acidic (HCl, 4.0), neutral (7.0) and alkaline (KOH, 9.0) and alkaline methanolic solution (KOH, 9.0) pH medium after the exposure to light. Furthermore, the peak of the SZ photodegraded product (2,4-(N-2-hydroxypropyl) diaza-3-methyl-1-nitro-1,5-dione) was not observed at acidic pH (4.0) alkaline methanol solution (9.0) and neutral pH (7.0) (Fig. 3). The photodegraded product of SZ was found in non-methanolic alkaline medium at pH (9.0). A gradual loss in the peak of SZ from 318 nm to 310 nm with an increase in the peak at 209 nm has been observed in spectra with an isosbestic point at 295 nm (Fig. 4).




Fig. 2 Linearity plot of absorbance against the concentration of SZ




Fig. 3 Photolyzed aqueous SZ in different media: (a) neutral (b) alkaline (c) acidic (d) alkaline methanol




Fig. 4 Absorption spectra of photolyzed SZ emulgel formulation (EG 10) in citrate buffer (pH 9.0)

3.5. Accelerated Stability Studies of SZ Emulgels

The accelerated stability studies of different formulations of SZ emulgel were studied for 3 months at $40 \pm 2^\circ\text{C}$ at 75.5% RH. All the formulations of SZ emulgel were found to be smooth, homogenous, viscous and milky-like preparations (Fig. 5). The drug content (SZ) was also calculated (Table 5).



Fig. 5 Physical texture of SZ emulgel formulation (EG 10) after 3 months

Table 5 Validation of SZ in aqueous and emulgel preparations

Compound	Aqueous Solution	Emulgel Preparation
λ_{max} nm	320	318
Molar absorptivity (ϵ) $\text{M}^{-1} \text{cm}^{-1}$	9.52×10^3	
Linearity ^a		
Concentration range ($\text{M} \times 10^5$)	5-15	100-500
Slope	0.951 ± 0.014	
Intercept	0.025	
SD of Slope	± 0.03	
SE of Slope	0.970	
Recovery range (%)	98.4–101.4	
Accuracy (%) \pm SD	99.4 ± 0.28	
RSD (%)	1.18	
LOD ^d ($\text{M} \times 10^6$)	1.018	
LOQ ^e ($\text{M} \times 10^6$)	3.278	

Notes: RSD - relative standard deviation; LOD - limit of detection; LOQ - limit of quantification; SE - standard error, ^a the mean of five determinations

4. Discussion

4.1. Formulation of SZ Emulgel

The gelling agent carbopol 934 was used to formulate the emulgel. Carbopol 934 was used to increase the sustain release action of SZ from the emulgels. The duration of action of pilocarpine hydrogels made of carbopol in ophthalmic preparation was enhanced with thermal stability [21]. The matrix of carbopol hydrogel was not destroyed at high temperature. [22] observed the better stability and release profile of carbopol against hydroxypropyl methylcellulose in metronidazole emulgel.

Castor oil reduces inflammation and relieves pain. Castor oil moisturizer the skin and reduced the irritation and itching. It also possessed antibacterial activity [23]. Mainly liquid paraffin is preferred in the formulation of topical emulgel preparations [24]. In this study, liquid paraffin and castor oil were included as an oleaginous phase to formulate SZ emulgels. The main disadvantage of minerals and castor oil is to produce a laxative effect in oral preparations [1]. Castor oil has been found to be safer as compared to liquid paraffin with the least skin irritation and for the stable formulation of emulgels. Furthermore, castor oil also increased the permeability of the drug. [25] found an increase in the permeability of flurbiprofen in emulgel without penetration enhancers. The penetration of flurbiprofen in emulgel was directly related to the concentration of castor oil.

Glycerol and propylene glycol were used as humectants. They are also used as co-solvents in aqueous media [26]. Glycerol and propylene glycol have produced its effect on the viscosity of emulgel. Glycerol is also used as an emulsifier, whereas, propylene glycol acts as a penetration enhancer [27]. Glycerol increases the dispersion of ibuprofen with an

increase in the crystallization of the drug due to higher concentration of ibuprofen [28].

All formulations of SZ emulgel were opaque in appearance. The formulations of emulgel were consistent in appearance after proper mixing. The emulgel formulations were found stable with no phase separation and creaming. Furthermore, no signs of grittiness or gritty particles were noticed after applying them on the hands. Thus, it indicated a uniform mixing and homogenization of all ingredients in the emulgel formulations. Similarly, indomethacin [29], metronidazole [30], tioconazole [31], solanum lycopersicum-derived lycopene [32], ketoconazole [33], ibuprofen [28], ofloxacin [34] and *Annona squamosa* L extracts [35] formulations of emulgel has shown a white color with better homogeneity, which also impact on the viscosity and spreadability.

4.2. Accelerated Stability of SZ Emulgels

All SZ formulations of emulgel were shown stability in accelerated stability studies with a negligible change in viscosity. Carbopol is mechanically stable after long-term storage [36]. It has been documented that SZ is stable against hydrolytic degradation [20]. SZ is also stable to dry heat but destabilized in the presence of oxygen and possesses oxidative stress [37]. Several studies investigated the accelerated stability testing of different drugs and extracts formulated in emulgel preparations like metronidazole [30], indomethacin [29], tioconazole (31), *Solanum lycopersicum* derived lycopene [32] and extracts of *Annona squamosa* L. [35].

The pH values of SZ emulgel formulations have not changed significantly during the time of accelerated stability studies. The use of citrate buffer has played a major role in the stabilization of SZ emulgel formulations. Citric acid is hydrophilic and possesses antimicrobial properties. Moreover, it is also used as an antioxidant [38]. [39] found an increase in the stability of flucloxacillin in citrate buffer solution. Similarly, [40] observed the highest stability of protein in citrate buffer even at temperature at 40°C. Citric acid has been used as a buffer and as an antioxidant. Thus, the oxidative degradation of SZ in emulgel formulations was found to be negligible. Accelerated stability testing of vaginal emulgel was conducted for the delivery of IQP-0528 (pyrimidinedione analog) and observed negligible change in viscosity with no effect in the change in the release profile of the drug in carbopol emulgel [36]. The formulations of SZ emulgel containing castor oil have been found to be stable and homogeneity with no segregation in the oleaginous phase. Castor oil mainly consists of mono-saturated fatty acids where double bonds activate the oxidation reaction. It has been noted oxidation reaction of castor oil has been reduced compared to the induction of oxidation by a faster process [41]. [42] observed

significant stability of castor oil-based nanoemulsion for 6 months. There was no significant change in the mean droplet size at 37°C. The change in pH was observed due to the liberation of free fatty acid from castor oil. The main drawback in the formulation of castor oil-based nanoemulsion did not contain any buffering agent to stabilize the pH of the nanoemulsion preparation. The strong matrix system in gels stabilized the phases of emulgels and avoided the chances of creaming. [32] also found the stability of emulgel formulation containing liquid paraffin with no creaming and phase separation for 3 months. A centrifugation test confirmed the accelerated stability of the emulgel formulation.

4.3. Photolysis of SZ

The photolysis of SZ mainly occurred due to photooxidation [43]. The rate of photolysis of SZ was the least found in EG 10 and EG 08 formulation, respectively (Fig. 6). The viscosity of emulgel preparations played a key role in the photooxidation of SZ in the emulgel formulations. The increase in the viscosity of emulgel formulations has reduced the rate constant (kobs) of the photolysis of SZ. Thus, the formulations of SZ emulgel containing glycerol have shown more photostability compared to propylene glycol. The penetration of oxygen was minimized due to the viscosity of the glycerol. The viscosity is decreased by increasing in temperature that may leads to phase separation, coalescence and creaming. Emulgels are stable at higher temperature due to strong matrix system allow to produce a stable and safe drug delivery system [32].




Fig. 6 SZ content in emulgel preparations against accelerated stability testing days

The photooxidation of SZ may lead to the formation of 2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione (photodegraded product, It has been supposed that endoperoxide may lead to the transformation to the dioxetane intermediate that then form the end product. The nitroimidazole drugs may undergo photooxidation and decreases the intensity of spectrometric absorption [43].

4.4. Thin Layer Chromatography (TLC) of SZ

Photolyzed emulgel preparations of SZ were studied by TLC. Pure SZ with photolyzed product of SZ (2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione) with alone SZ was determined in all formulations of SZ emulgel. The intensity of SZ was found greater in intensity of viscous emulgel. The spots were determined under UV light (209 nm) [44]. Similarly, the photodegradation of riboflavin was observed by [45]. Pure SZ spot intensity of emulgel was reduced due to difference in viscosity of different formulations of emulgel. [46] reported the formation of (2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione) by photooxidation of SZ.

4.5. Absorption Characteristics of Photolysed SZ

SZ was instable at alkaline pH [37]. A UV-visible spectrophotometer was used to assay pure and photolyzed SZ emulgel preparations in alkaline pH (9.0, SZ emulgel (1%, w/w) was diluted to 10 mg of SZ concentration in a diluted solution. 2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione photodegraded product of SZ) was observed at 209 nm in only alkaline medium (KOH, pH 9.0) no photodegradation product was observed in alkaline methanol, acidic and neutral medium (Fig. 3). The method has been found to be precise, accurate and selective for all w/o SZ emulgel formulations. It has also been observed that the prolonged exposure of light on SZ pure aqueous solution and emulgel formulations has eliminated the peak at 209 nm, as already reported by [46].

The spectrum of the photolyzed SZ emulgel formulation (EG 10) peak (λ_{max}) has been revealed at 318 nm. As it has been observed, the peak (λ_{max}) of photolyzed product of SZ was observed only in alkaline medium (KOH; pH 9.0) at 209 nm. A decrease was in the absorption of photolyzed SZ preparation with a span of 30 min interval. The peak of the end photodegraded product of SZ, 2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione was not shown in neutral, acidic and methanolic alkaline media (Fig. 3). The change in the peak of SZ was observed at 277 and 311 in acidic (4.0) and neutral (7.0), respectively. The change in pH may cause a bathochromic shift of peak (λ_{max}) of drugs [47]. A bathochromic shift of the norfloxacin peak was also observed by [48]. The photolyzed emulgel of SZ formulations shows the peak of the photodegraded product of SZ at 211 nm with the presence of an isosbestic point at 295 nm, indicating the formation of a single photodegraded product of SZ (2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione) in alkaline medium (KOH; pH 9.0) [44]. It was noted that the photodegraded product peak was diminished after a longer exposure to light. [49] reported the photodegradation of SZ product after prolong exposure

of light.

4.6. Application of the Assay Method

The two-component spectrometric method was used to analyze SZ and its photoproduct 2,4-(N-2-hydroxypropyl)diaza-3-methyl-1-nitro-1,5-dione at 318 and 209 nm, respectively. The analysis method has been validated for the application of assay of SZ and its photoproduct (Table 5). The two-component method has also been used in the analysis of riboflavin, thiamine and cyanocobalamin and their photoproducts [12, 45, 50, 51]. There was no significant interference in the absorption was observed in the spectra of control empty emulgel formulations between 600 and 200 nm due to the extraction of the oleaginous phase by chloroform in HCl-KCl buffer pH 2.0. Extraction at pH 2.0 increased the ionization constant of SZ [52]. The increase in the ionization constant of SZ in highly acidic pH has increased the polarity of SZ [53]. Thus, the chances of SZ solubility in chloroform have been minimized. Castor oil is easily miscible in chloroform, whereas, liquid paraffin is freely soluble in chloroform [54]. The separation of the oleaginous phase from emulgel by chloroform reduced the chances of interference in the analysis of SZ and its photoproduct.

4.7. Kinetics of Photodegradation of SZ

The photolysis of SZ in emulgel formulation followed clear first-order kinetics. A plot of the log concentration of SZ versus time determined the clear first-order rate constants (k_{obs}) of SZ. The formulation characteristics of SZ emulgel preparations significantly affect the rate of reaction. The following factors were studied which may effect on the rate constant of SZ in the formulation of emulgel.

4.7.1. Effects on the Viscosity of SZ Emulgels

The viscosity affected the stability of SZ emulgel formulations. The viscosity of the formulations may significantly impact the stability [55]. The increase in the viscosity of SZ emulgel formulations with an increase in the concentration of humectants (propylene glycol and glycerol) and oil phase (castor and liquid paraffin), The increase in shearing force decreases the viscosity of emulgels, shown with non-Newtonian flow; mainly this has occurred due to its low flow resistance when applied at high shear conditions [56]. The reduction in viscosity of SZ emulgel formulations has possessed pseudoplastic behavior. The high characteristic of spreadability was observed with a decrease in viscosity of SZ emulgel formulations. Thus, by increasing the concentration of humectants, the spreadability of SZ emulgels was increased. The increase in the viscosity of the emulgel has decreased the photodegradation of SZ in the emulgel. The increase in viscosity hinders the motion of molecules and reduces the particular photochemical reactions

[57]. The effect of viscosity on the spreadability and k_{obs} is shown in Fig. 7.




Fig. 7 Effect of viscosity against k_{obs} and spreadability of SZ emulgel formulations

4.7.2. Effects of Humectants on SZ Emulgels

Humectants moistened pharmaceutical preparations and were also used to improve the readability. The viscosity of glycerol and propylene glycol are ~935 and ~41 mPa/s, respectively. A linear relationship of photodegradation versus the reciprocal of viscosity indicates that the rate of photodegradation depends on the viscosity of the medium. [55] reported a linear relationship between k_{obs} and viscosity in the photolysis of riboflavin. The viscosity of the pharmaceutical preparation significantly affects the stability of oxidizable drugs [58]. Oxidation metabolized SZ [6]. It has been observed that with an increase in the concentration of humectants (propylene glycol and glycerol) the viscosity of emulgel was increased and it may affect on the photostability of SZ. The lowest rate of photolysis of SZ in emulgel formulation (EG 10) was observed due to the highest concentration of glycerol. The addition of glycerol reduced the photodegradation of cyanocobalamin in aqueous solution. The viscosity may reduce the penetration of oxygen in the viscous pharmaceutical preparation. Thus, the chances of photooxidation of SZ were reduced [59]. [60] found the antioxidant property of glycerol, which may be enhanced oxidative stability of quercetin. [61] observed that the rate of photolysis of riboflavin was reduced by the addition of glycerol. Riboflavin reacted with glycerol, which acts as an electron donor. The decrease in quantum yield is mainly due to the viscosity of glycerol. Thus, an increase in viscosity achieved photostabilization [62].

4.7.3. Effects of the Oil Phase on SZ Emulgels

Castor oil and mineral oils were used in the formulation of SZ emulgel. These were also used in emulgel formulations to modify the characteristics of pharmaceutical vehicles on the skin for better penetration of the active drug. It was observed that the k_{obs} of the SZ in the emulgel changed with the concentration of the oil phase. Liquid paraffin (mineral oil) containing emulgel formulations increased in rate of SZ degradation. [63] found that the photostability of

the avobenzone was achieved by the mineral oil. However, emulgels containing castor oil showed better stability. Castor oil has shown oxidative stability [64]. In case of increasing the concentration of castor oil in nanoemulgels, the system stability also increases [65]. The dosage form and the excipients generally ascertain the photostability of the drugs [66]. [67] observed the stability of nevirapine by the use of liquid paraffin for emulsification in castor oil-based chitosan microemulsion. Oxygen plays an important role in the photolysis of drug. The photolysis of primaquine was investigated under the influence of oxygen. It was observed that the photostability of primaquine has decreased [68]. Similarly, [41] also found the stability of castor oil and mineral oil. The thermo-oxidative stability of bio-based products compared to petroleum-based lubricants and vegetable oils determined through the PetroOXY method. The photostability of tretinoin in castor oil was determined in [69]. Castor oil is more stable against oxidation than other vegetable oils [70].

5. Conclusion

This study involves the formulation of different emulgels with the variations in humectants and oil phases and its effect on stabilization of SZ. It has been observed that an increase in the concentration of castor oil and glycerol increased the viscosity of emulgel preparations. This may affect the rate of photolysis of SZ. The rate constant for the degradation of SZ has been observed to decrease with an increase in the concentration of castor oil and glycerol. Thus, the viscosity of emulgel is one of the prime considerations to decrease the photolysis of the drug. The chances of entrapment of oxygen and hindrance of molecules are also reduced. Therefore, it improves the stability of a drug and prolongs its shelf-life.

References

- [1] TANAJI D.N. Emulgel: a comprehensive review for topical delivery of hydrophobic drugs. *Asian Journal of Pharmaceutics*, 2018, 12(2): 45-52.
- [2] AMRA K., MOMIN M., DESAI N., and KHAN F. Therapeutic benefits of natural oils along with permeation enhancing activity. *International Journal of Dermatology*, 2021. DOI: 10.1111/ijd.15733
- [3] BARNES T.M., MIJALJICA D., TOWNLEY J.P., SPADA F., and HARRISON I.P. Vehicles for drug delivery and cosmetic moisturizers: review and comparison. *Pharmaceutics*, 2021, 13(12): 2012.
- [4] TALAT M., ZAMAN M., KHAN R., JAMSHAD M., AKHTAR M., and MIRZA A.Z. Emulgel: an effective drug delivery system. *Drug Development and Industrial Pharmacy*, 2021. DOI: 10.1080/03639045.2021.1993889
- [5] VERMA A., JOSHI S., and SINGH D. Imidazole: having versatile biological activities. *Journal of Chemistry*, 2013, Article ID 329412.
- [6] HASSAN S., ARSALAN A., BAIG M.T., SYED N., IBRAHIM S., ALI S., HUMA A., JABEEN A., NAEEM M., and ARIF J. Factors affecting the formulation for the

- stabilization of secnidazole in gel preparations. *Pharmacophore*, 2021, 12(1): 15-23.
- [7] NYIRJESY P., and SCHWEBKE J.R. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. *Future Microbiology*, 2018, 13(5): 507-524.
- [8] SHOVKOVA O.V., KLIMENKO L.Y., KOVALENKO S.M., and ZHUKOVA T.V. Development and validation of UV-spectrophotometric procedures for secnidazole quantitative determination. *Journal of Pharmaceutical Sciences and Research*, 2017, 9(4): 338-348.
- [9] MARCILIO M.R., RAISER A.L., FUMAGALLI L.P., BONFILIO R., ANDRIGHETTI C.R., RIBEIRO E.B., and DE SOUSA VALLADAO D.M. Determination and validation of secnidazole in tablets by UV spectrophotometric. *Bioscience Journal*, 2017, 33(5): 1351-1361.
- [10] GUPTA R.S., DESHMUKH R.R., RANDIVE P.U., KSHIRSAGAR A.V., and KAYTE J.N. Study of pharmaceutical solid dosage forms using invasive and non invasive techniques: a review. *Journal of Environmental Science, Computer Science and Engineering & Technology*, 2018, 7(3): 321-327.
- [11] RELE R.V. Derivative spectrophotometric method for estimation of secnidazole in bulk and pharmaceutical dosage form. *Asian Journal of Research in Chemistry*, 2019, 12(2): 71-74.
- [12] ARSALAN A., AHMAD I., ALI S.A., QADEER K., MAHMUD S., HUMAYUN F., and BEG A.E. The kinetics of photostabilization of cyanocobalamin in liposomal preparations. *International Journal of Chemical Kinetics*, 2020, 52(3): 207-217.
- [13] QADEER K., ARSALAN A., AHMAD I., FATIMA K., ANWAR Z., AHMED S., KHATTAK S.R., and MAHMUD S. Photochemical interaction of cyanocobalamin and hydroxocobalamin with cysteine. *Journal of Molecular Structure*, 2021: 129441.
- [14] OSMAN R.M., DAFAALLA S.A., SIDDIG S.S., AHMED W.N., and ADAM M.E. Development and validation of difference spectrophotometric method for the determination of secnidazole in bulk and tablet dosage forms. *World Journal of Pharmaceutical Sciences*, 2019, 8(11): 1354-1362.
- [15] UBAID M., ILYAS S., MIR S., KHAN A.K., RASHID R., KHAN M.Z., KANWAL Z.G., NAWAZ A., SHAH A., and MURTAZA G. Formulation and in vitro evaluation of carbopol 934-based modified clotrimazole gel for topical application. *Annals of the Brazilian Academy of Sciences*, 2016, 88(4): 2303-2317.
- [16] PRAJAPATI R., PATEL J., and PATEL A. Nanoparticles containing gel formulation for the treatment of psoriasis. *International Journal of Pharmaceutical Investigation*, 2021, 11(1): 76-81.
- [17] ARSALAN A., QADEER K., ALI S.A., AHMED S., KHAN R.A., SHERAZ M.A., HASSAN S., and AHMAD I. The effect of albumin in photostabilization of riboflavin: A kinetic study. *Journal of Photochemistry and Photobiology A: Chemistry*, 2020, 394: 112456.
- [18] BADAWI N.M., ELKAFRAWY M.A., YEHIA R.M., and ATTIA D.A. Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence. *Drug Delivery*, 2021, 28(1): 814-825.
- [19] SHUKLA K.V., MESHRAM R., and YADAV M. Formulation, development and evaluation of transfersomal gel of metronidazole. *Journal of Drug Delivery and Therapeutics*, 2019, 9(4): 640-645.
- [20] KHAN S., HASEEB M., BAIG M.H., BAGGA P.S., SIDDIQUI H.H., and KAMAL M.A. Improved efficiency and stability of secnidazole-an ideal delivery system. *Saudi Journal of Biological Sciences*, 2015, 22(1): 42-49.
- [21] DESHPANDE S.G., and SHIROLKAR S. Sustained release ophthalmic formulations of pilocarpine. *Journal of Pharmacy and Pharmacology*, 1989, 41(3): 197-200.
- [22] DAWOOD N.M., JASSIM Z.E., GAREEB M.M., and ZEKI H.I. Studying the effect of different gelling agents on the preparation and characterization of metronidazole as topical emulgel. *Asian Journal of Pharmaceutical and Clinical Research*, 2019, 12(3): 571-577.
- [23] HON K.L., KUNG J.S., NG W.G., and LEUNG T.F. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. *Drugs in Context*, 2018, 7: 212530.
- [24] RANJAN P., JAIN V., SHENDE S., and JAIN P.K. Formulation development and evaluation of emulgel of clindamycin phosphate for effective treatment of acne. *Journal of Drug Delivery Science and Technology*, 2019, 9(4): 202-207.
- [25] ALAAYEDI M., MAHMOOD H., and SAEED A. The enhancement effect of castor oil on the permeability of flurbiprofen as transdermal gel. *International Journal of Applied Pharmaceutics*, 2018, 10(1): 140-144.
- [26] KHALIL E.A., MAJID S.A., SUAIFAN G.A., AL-AKAYLEH F.T., and SALLAM A.S. Physicochemical characterization of emulgel formulated with SepineoP 600, SepineoSE 68 and cosolvent mixtures. *Pharmaceutical Development and Technology*, 2016, 21(5): 519-527.
- [27] ASHARA K., SONIWALA M., and SHAH K. Emulgel: a novel drug delivery system. *Journal of Pakistan Association of Dermatologists*, 2017, 26(3): 244-249.
- [28] BOLLA P.K., CLARK B.A., JULURI A., CHERUVU H.S., and RENUKUNTLA J. Evaluation of formulation parameters on permeation of ibuprofen from topical formulations using Strat-M® membrane. *Pharmaceutics*, 2020, 12(2): 151.
- [29] MULYE S.P., WADKAR K.A., and KONDAWAR M.S. Formulation development and evaluation of indomethacin emulgel. *Der Pharmacia Sinica*, 2013, 4(5): 31-45.
- [30] RAO M., SUKRE G., AGHAV S., and KUMAR M. Optimization of metronidazole emulgel. *Bulletin of Faculty of Pharmacy, Cairo University*, 2013, Article ID 501082.
- [31] SAH S.K., BADOLA A., and MUKHOPADHYAY S. Development and evaluation of tioconazole loaded emulgel. *International Journal of Applied Pharmaceutics*, 2017, 9(5): 83-90.
- [32] SOHAIL M., NAVEED A., ABDUL R., KHAN H.M., and KHAN H. An approach to enhanced stability: Formulation and characterization of Solanum lycopersicum derived lycopene based topical emulgel. *Saudi Pharmaceutical Journal*, 2018, 26(8): 1170-1177.
- [33] PRANALI S., CHARUSHILA S., SAYALI C., and NAMRATA M. Design and characterisation of emulgel of an antifungal drug. *International Journal of Pharmaceutical Sciences and Research*, 2019, 11(6): 2357-2361.
- [34] JAGDALE S., and PAWAR S. Gellified emulsion of ofloxacin for transdermal drug delivery system. *Advanced*

Pharmaceutical Bulletin, 2017, 7(2): 229-239.

[35] MEER S., ASLAM S., ABBASI M.S., and TAHIR M.A. Preparation and characterization of natural antioxidant emulgels loaded with *Annona squamosa L.* extract with and without penetration enhancer. *Asian Journal of Research in Dermatological Science*, 2020, 3(3): 1-10.

[36] MAHALINGAM A., SIMMONS A.P., UGAONKAR S.R., WATSON K.M., DEZZUTTI C.S., ROHAN L.C., BUCKHEIT J.R.W., and KISER P.F. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. *Antimicrobial Agents and Chemotherapy*, 2011, 55(4): 1650-1660.

[37] BAKSHI M., and SINGH S. ICH guidance in practice: establishment of inherent stability of secnidazole and development of a validated stability-indicating high-performance liquid chromatographic assay method. *Journal of Pharmaceutical and Biomedical Analysis*, 2004, 36(4): 769-775.

[38] RYAN E.M., DURYEE M.J., HOLLINS A., DOVER S.K., PIRRUCCELLO S., SAYLES H., REAL K.D., HUNTER C.D., THIELE G.M., and MIKULS T.R. Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid. *Journal of Pharmaceutical and Biomedical Analysis*, 2019, 164: 460-466.

[39] ALLWOOD M.C., STONKUTE D., WALLACE A., WILKINSON A.S., HILLS T., and JAMIESON C. Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INFusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. *European Journal of Hospital Pharmacy*, 2020, 27(2): 90-94.

[40] ZBACNIK T.J., HOLCOMB R.E., KATAYAMA D.S., MURPHY B.M., PAYNE R.W., COCCARO R.C., EVANS G.J., MATSUURA J.E., HENRY C.S., and MANNING M.C. Role of buffers in protein formulations. *Journal of Pharmaceutical Sciences*, 2017, 106(3): 713-733.

[41] LUNA F.M., SALMIN D.C., SANTIAGO V.S., MAIA F.J., SILVA F.O., MAZZETTO S.E., and CAVALCANTE C.L. Oxidative stability of acylated and hydrogenated ricinoleates using synthetic and natural antioxidants. *Journal of Chemistry*, 2019, Article ID 3973657.

[42] TAMILVANAN S., KUMAR B.A., SENTHILKUMAR S.R., BASKAR R., and SEKHARAN T.R. Stability assessment of injectable castor oil-based nano-sized emulsion containing cationic droplets stabilized by poloxamer-chitosan emulsifier films. *AAPS PharmSciTech*, 2010, 11(2): 904-909.

[43] LIMA J., KOGAWA A., and SALGADO H. Green analytical method for quantification of secnidazole in tablets by HPLC-UV. *Drug Analytical Research*, 2018, 2(2): 20-26.

[44] AZZA A., MOUSTAFA L.I., and BIBAWY L.I. Stability indicating assay of secnidazole in the presence of its degradation products. *Spectroscopy Letters*, 1999, 32(6): 1073-1098.

[45] AHMAD I., ARSALAN A., SHERAZ M.A., AHMED S., ANWAR Z., and MUNIR I. Formulation and stabilization of riboflavin in liposomal preparations. *Journal of Photochemistry and Photobiology B: Biology*, 2015, 153: 358-366.

[46] LARINA L., and LOPYREV V. *Nitroazoles: Synthesis,*

Structure and Applications. 1st ed. Springer, Dordrecht, Heidelberg, London, 2009.

[47] MASOUD M., ELSAMRA R.M.I., and HEMDAN S. Solvent, substituents and pH effects towards the spectral shifts of some highly colored indicators. *Journal of the Serbian Chemical Society*, 2017, 82: 32-32.

[48] AHMAD I., ARSALAN A., ALI S.A., BANO R., MUNIR I., and SABAH A. Formulation and stabilization of norfloxacin in liposomal preparations. *European Journal of Pharmaceutical Sciences*, 2016, 91: 208-215.

[49] LARINA L.I., and LOPYREV V.A. Synthesis of nitrobenzazoles. Part 1. In: ATTANASI O.A., and SPINELLI D. (eds.). *Targets in Heterocyclic Systems-Chemistry and Properties*. Italian Society Chemistry: Rome, Italy, 2005, 9, pp. 327-365.

[50] AHMAD I., ABBAS S.H., ANWAR Z., SHERAZ M.A., AHMED S., ARSALAN A., and BANO R. Stability-indicating photochemical method for the assay of riboflavin: lumichrome method. *Journal of Chemistry*, 2015, Article ID 256087.

[51] AHMAD I., ANWAR Z., IQBAL K., ALI S.A., MIRZA T., ADEELA A.A, KHURSHID A., and ARSALAN A. Effect of acetate and carbonate buffers on the photolysis of riboflavin in aqueous solution: a kinetic study. *AAPS PharmSciTech*, 2014, 15(3): 550-559

[52] DARWISH K.M., SALAMA I., MOSTAFA S., and EL-SADEK M. Extractational spectrophotometric analysis of metronidazole, tinidazole, ornidazole and secnidazole bases through acid-dye complexation using bromothymol blue dye. *Pakistan Journal of Pharmaceutical Sciences*, 2012, 25(1): 207-217.

[53] SINGH A., PATHAK D., and PATHAK K. Use of Microporous Accurel MP1000 for Duodenal Delivery of Secnidazole: A High dose, gastric pH unstable drug. *International Journal of Drug Delivery Technology*, 2010, 2(2): 26-34.

[54] DRUG FUTURE. *Drug Standard Database*. Pharmacopoeia.

https://www.drugfuture.com/Pharmacopoeia/USP32/pub/dat/v32270/usp32nf27s0_alpha-2-12.html (Accessed on 17th Jan, 2022)

[55] AHMAD I., ANWAR Z., AHMED S., SHERAZ M.A., BANO R., and HAFEEZ A. Solvent effect on the photolysis of riboflavin. *AAPS PharmSciTech*, 2015, 16(5): 1122-1128.

[56] DANTAS M.G.B., REIS S.A.G.B., DAMASCENO C.M.D., ROLIM L.A, ROLIM-NETO P.J., CARVALHO F.O., QUINTANS-JUNIOR L.J., and DA SILVA ALMEIDA J.R.G. Development and evaluation of stability of a gel formulation containing the monoterpene borneol. *The Scientific World Journal*, 2016: Article ID 7394685

[57] HINKS M.L., BRADY M.V., LIGNELL H., SONG M., GRAYSON J.W., BERTRAM A.K., LIN P., LASKIN A., LASKIN J., and NIZKORODOV S.A. Effect of viscosity on photodegradation rates in complex secondary organic aerosol materials. *Physical Chemistry Chemical Physics*, 2016, 18(13): 8785-8793.

[58] LAIDLER K.J. A glossary of terms used in chemical kinetics, including reaction dynamics (IUPAC Recommendations 1996). *Pure and Applied Chemistry*, 1996, 68(1): 149-192.

[59] GRISSOM C.B., CHAGOVETZ A.M., and WANG Z. Use of viscosogens to stabilize vitamin B12 solutions against photolysis. *Journal of Pharmaceutical Sciences*, 1993, 82(6):

641-643.

[60] JERZYKIEWICZ M., CWIELAG I., and JERZYKIEWICZ W. The antioxidant and anticorrosive properties of crude glycerol fraction from biodiesel production. *Journal of Chemical Technology & Biotechnology*, 2009, 84(8): 1196-1201.

[61] CAIRNS W.L., and METZLER D.E. Photochemical degradation of flavins. VI. A new photoproduct and its use in studying the photolytic mechanism. *Journal of the American Chemical Society*, 1971, 93(11): 2772-2777.

[62] AHMAD I., AHMED S., ANWAR Z., SHERAZ M.A., and SIKORSK M. Photostability and photostabilization of drugs and drug products. *International Journal of Photoenergy*, 2016: Article ID 8135608.

[63] VALLEJO J.J., MESA M., and GALLARDO C. Evaluation of the avobenzone photostability in solvents used in cosmetic formulations. *Vitae*, 2011, 18(1): 63-71.

[64] DOS SANTOS POLITI J.R., DE MATOS P.R., and SALES M.J. Comparative study of the oxidative and thermal stability of vegetable oils to be used as lubricant bases. *Journal of Thermal Analysis and Calorimetry*, 2013, 111(2): 1437-1442.

[65] MAO Y., CHEN X., XU B., SHEN Y., YE Z., CHAURASIYA B., LIU L., LI Y., XING X., and CHEN D. Eprinomectin nanoemulgel for transdermal delivery against endoparasites and ectoparasites: preparation, in vitro and in vivo evaluation. *Drug Delivery*, 2019, 26(1): 1104-1114.

[66] BAERTSCHI S.W., CLAPHAM D., FOTI C., KLEINMAN M.H., KRISTENSEN S., REED R.A., TEMPLETON A.C., and TONNESEN H.H. Implications of in-use photostability: Proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 2: Topical drug product. *Journal of Pharmaceutical Sciences*, 2015, 104(9): 2688-2701.

[67] BAJAJ H., BISHT S., YADAV M., SINGH V., and SINGH M. Design and development of nevirapine loaded surfactant free chitosan microemulsion. *Acta Poloniae Pharmaceutica*, 2011, 68(6): 981-988.

[68] KRISTENSEN S. Photoreactivity of biologically active compounds. XVII. Influence of solvent interactions on spectroscopic properties and photostability of primaquine. *Pharmazie*. 2005, 60(6): 426-433.

[69] BRISAERT M., and PLAIZIER-VERCAMMEN J.A. Investigation on the photostability of tretinoin in creams. *International Journal of Pharmaceutics*, 2007, 334(1-2): 56-61.

[70] YEBOAH A., YING S., LU J., XIE Y., AMOANIMAA-DEDE H., BOATENG K.G.A., CHEN M., and YIN X. Castor oil (*Ricinus communis*): a review on the chemical composition and physicochemical properties. *Journal of Food Science and Technology*, 2021, 41(Suppl. 2): 399-413.

參考文:

[1] TANAJI D.N. 乳膠：疏水性藥物局部給藥的全面綜述。亞洲藥學雜誌, 2018, 12(2): 45-52.

[2] AMRA K., MOMIN M., DESAI N. 和 KHAN F. 天然油的治療益處以及滲透增強活性。國際皮膚病學雜誌, 2021 年。DOI: 10.1111/ijd.15733

[3] BARNES T.M., MIJALJICA D., TOWNLEY J.P.,

SPADA F. 和 HARRISON I.P. 藥物輸送和化妝品保濕劑的載體：回顧和比較。藥劑學, 2021, 13(12): 2012.

[4] TALAT M., ZAMAN M., KHAN R., JAMSHAI D. M., AKHTAR M. 和 MIRZA A.Z. 乳膠：一種有效的藥物輸送系統。藥物開發與工業製藥, 2021。DOI: 10.1080/03639045.2021.1993889

[5] VERMA A., JOSHI S. 和 SINGH D. 咪唑：具有多種生物活性。化學雜誌, 2013 年, 文章編號 329412.

[6] HASSAN S., ARSALAN A., BAIG M.T., SYED N., IBRAHIM S., ALI S., HUMA A., JABEEN A., NAEEM M. 和 ARIF J. 影響配方穩定性的因素 凝膠製劑中的塞克硝唑。藥效團, 2021, 12(1): 15-23.

[7] NYIRJESY P. 和 SCHWEBKE J.R. 塞克硝唑：用於治療細菌性陰道病的下一代抗菌劑。未來微生物學, 2018, 13(5): 507-524.

[8] SHOVKOVA O.V., KLIMENKO L.Y., KOVALENKO S.M. 和 ZHUKOVA T.V. 用於塞克硝唑定量測定的紫外分光光度法程序的開發和驗證。藥物科學研究雜誌, 2017, 9(4): 338-348.

[9] MARCILIO M.R., RAISER A.L., FUMAGALLI L.P., BONFILIO R., ANDRIGHETTI C.R., RIBEIRO E.B. 和 DE SOUSA VALLADAO D.M. 紫外分光光度法測定和驗證片劑中塞克硝唑的含量。生物科學雜誌, 2017, 33(5): 1351-1361.

[10] GUPTA R.S., DESHMUKH R.R., RANDIVE P.U., KSHIRSAGAR A.V. 和 KAYTE J.N. 使用侵入性和非侵入性技術研究藥物固體劑型：綜述。環境科學學報, 計算機科學與工程技術, 2018, 7(3): 321-327.

[11] RELE R.V. 用於估計散裝和藥物劑型中塞克硝唑的導數分光光度法。亞洲化學研究雜誌, 2019, 12(2): 71-74.

[12] ARSALAN A., AHMAD I., ALI S.A., QADEER K., MAHMUD S., HUMAYUN F. 和 BEG A.E. 脂質體製劑中氰鈷胺的光穩定動力學。國際化學動力學雜誌, 2020, 52(3): 207-217.

[13] QADEER K., ARSALAN A., AHMAD I., FATIMA K., ANWAR Z., AHMED S., KHATTAK S.R. 和 MAHMUD S. 氰鈷胺和羧鈷胺與半胱氨酸的光化學相互作用。分子結構雜誌, 2021: 129441.

[14] OSMAN R.M., DAFAALLA S.A., SIDDIG S.S., AHMED W.N. 和 ADAM M.E. 開發和驗證用於測定散裝和片劑劑型中塞克硝唑的差異分光光度法。世界藥學雜誌, 2019, 8(11): 1354-1362.

[15] UBAID M., ILYAS S., MIR S., KHAN A.K., RASHID R., KHAN M.Z., KANWAL Z.G., NAWAZ A., SHAH A. 和 MURTAZA G. 基於卡波姆 934 的配方和體外評估 用於局部應用的改性克黴唑凝膠。巴西科學院年鑑, 2016 年, 88(4): 2303-2317.

[16] PRAJAPATI R., PATEL J. 和 PATEL A. 含有用於治療牛皮癬的凝膠製劑的納米顆粒。國際藥物研究雜誌, 2021, 11(1): 76-81.

[17] ARSALAN A., QADEER K., ALI S.A., AHMED S., KHAN R.A., SHERAZ M.A., HASSAN S. 和 AHMAD I. 白蛋白對核黃素光穩定性的影響：一項動力學研究。光化學與光生物學雜誌 一種：化學, 2020, 394: 112456.

[18] BADAWI N.M., ELKAFRAWY M.A., YEHIA R.M.

和 ATTIA D.A. 優化甲硝唑脂質納米載體陰道乳劑治療細菌性陰道病及其複發的臨床比較研究。藥物輸送, 2021, 28(1): 814-825。

[19] SHUKLA K.V., MESHRAM R. 和 YADAV M. 甲硝唑轉移體凝膠的配製、開發和評價。藥物輸送和治療學雜誌, 2019, 9(4): 640-645。

[20] KHAN S., HASEEB M., BAIG M.H., BAGGA P.S., SIDDIQUI H.H. 和 KAMAL M.A. 提高塞克硝唑的效率和穩定性——一種理想的輸送系統。沙特生物科學雜誌, 2015年, 22(1): 42-49。

[21] DESHPANDE S.G. 和 SHIROLKAR S. 毛果芸香鹼的緩釋眼用製劑。藥學與藥理學雜誌, 1989, 41(3): 197-200。

[22] DAWOOD N.M., JASSIM Z.E., GAREEB M.M. 和 ZEKI H.I. 研究不同膠凝劑對甲硝唑外用乳膠劑製備及表徵的影響。亞洲藥物與臨床研究雜誌, 2019, 12(3): 571-577。

[23] HON K.L., KUNG J.S., NG W.G. 和 LEUNG T.F. 特應性皮炎的潤膚劑治療: 最新證據和臨床考慮。相關藥物, 2018年, 7: 212530。

[24] RANJAN P., JAIN V., SHENDE S. 和 JAIN P.K. 有效治療痤瘡的克林黴素磷酸酯乳膠劑的製劑開發及評價給藥科學與技術雜誌, 2019, 9(4): 202-207。

[25] ALAAYEDI M., MAHMOOD H. 和 SAEED A. 蓖麻油對氟比洛芬透皮凝膠滲透性的增強作用。國際應用藥劑學雜誌, 2018, 10(1): 140-144。

[26] KHALIL E.A., MAJID S.A., SUAIFAN G.A., AL-AKAYLEH F.T. 和 SALLAM A.S. 用海派諾 P 600、海派諾 SE 68 和共溶劑混合物配製的乳膠的物理化學特性。藥物開發與技術, 2016, 21(5): 519-527。

[27] ASHARA K., SONIWALA M. 和 SHAH K. 乳膠: 一種新型藥物輸送系統。巴基斯坦皮膚科醫生協會雜誌, 2017年, 26(3): 244-249。

[28] BOLLA P.K., CLARK B.A., JULURI A., CHERUVU H.S. 和 RENUKUNTLA J. 使用 Strat-M®膜評估布洛芬從局部製劑中滲透的製劑參數。藥劑學, 2020, 12(2): 151。

[29] MULYE S.P., WADKAR K.A. 和 KONDAWAR M.S. 吡啶美辛乳膠劑的配方開發與評價。中國製藥, 2013, 4(5): 31-45。

[30] RAO M., SUKRE G., AGHAV S. 和 KUMAR M. 甲硝唑乳膠的優化。開羅大學藥學院公告, 2013年, 文章 ID 501082。

[31] SAH S.K., BADOLA A. 和 MUKHOPADHYAY S. 噻康唑負載乳膠的開發和評估。國際應用藥劑學雜誌, 2017, 9(5): 83-90。

[32] SOHAIL M., NAVEED A., ABDUL R., KHAN H.M. 和 KHAN H. 增強穩定性的方法: 基於番茄紅素的番茄紅素外用乳膠的配方和表徵。沙特製藥雜誌, 2018年, 26(8): 1170-1177。

[33] PRANALI S., CHARUSHILA S., SAYALI C. 和 NAMRATA M. 抗真菌藥物乳膠的設計和表徵。國際藥物科學研究雜誌, 2019, 11(6): 2357-2361。

[34] JAGDALE S. 和 PAWAR S. 用於透皮給藥系統的氧氟沙星凝膠化乳液。高級藥物通報, 2017, 7(2): 229-239。

[35] MEER S., ASLAM S., ABBASI M.S. 和 TAHIR

M.A. 天然抗氧化乳膠的製備和表徵, 其中含有番荔枝提取物, 含有和不含滲透促進劑。亞洲皮膚病學研究雜誌, 2020, 3(3): 1-10。

[36] MAHALINGAM A., SIMMONS A.P., UGAONKAR S.R., WATSON K.M., DEZZUTTI C.S., ROHAN L.C., BUCKHEIT J.R.W. 和 KISER P.F. 用於遞送智商計劃-0528 的陰道殺菌劑凝膠, 這是一種嘧啶二酮類似物, 具有針對艾滋病病毒-1 的雙重作用機制。抗菌藥物與化療, 2011, 55(4): 1650-1660。

[37] BAKSHI M. 和 SINGH S. 人用藥品註冊技術要求國際協調委員會實踐指南: 塞克硝唑固有穩定性的建立和經過驗證的穩定性指示高效液相色譜分析方法的開發。藥物與生物醫學分析雜誌, 2004, 36(4): 769-775。

[38] RYAN E.M., DURYEE M.J., HOLLINS A., DOVER S.K., PIRRUCCELLO S., SAYLES H., REAL K.D., HUNTER C.D., THIELE G.M. 和 MIKULS T.R. 檸檬酸的抗氧化特性會干擾基於尿酸酶的循環尿酸測量。藥物與生物醫學分析雜誌, 2019, 164: 460-466。

[39] ALLWOOD M.C., STONKUTE D., WALLACE A., WILKINSON A.S., HILLS T. 和 JAMIESON C. 評估檸檬酸鹽緩衝氟氯西林在兩種市售流動彈性裝置中的穩定性: 輸液器低壓 (百特) 和蓄能器 (和榮醫療): 一項符合國民健康保險制度黃色封面文件要求的研究。歐洲醫院藥學雜誌, 2020, 27(2): 90-94。

[40] ZBACNIK T.J., HOLCOMB R.E., KATAYAMA D.S., MURPHY B.M., PAYNE R.W., COCCARO R.C., EVANS G.J., MATSUURA J.E., HENRY C.S. 和 MANNING M.C. 緩衝液在蛋白質配方中的作用。藥學雜誌, 2017, 106(3): 713-733。

[41] LUNA F.M., SALMIN D.C., SANTIAGO V.S., MAIA F.J., SILVA F.O., MAZZETTO S.E. 和 CAVALCANTE C.L. 使用合成和天然抗氧化劑的酰化和氫化蓖麻油酸酯的氧化穩定性。化學雜誌, 2019, 文章編號 3973657。

[42] TAMILVANAN S., KUMAR B.A., SENTHILKUMAR S.R., BASKAR R. 和 SEKHARAN T.R. 含有由泊洛沙姆-殼聚糖乳劑膜穩定的陽離子液滴的可注射蓖麻油基納米乳液的穩定性評估。美國藥學科學家協會 醫藥科技, 2010, 11(2): 904-909。

[43] LIMA J., KOGAWA A. 和 SALGADO H. 通過帶紫外檢測器的高壓液相色譜定量測定片劑中塞克硝唑的綠色分析方法。藥物分析研究, 2018, 2(2): 20-26。

[44] AZZA A., MOUSTAFA L.I. 和 BIBAWY L.I. 塞克硝唑在其降解產物存在下的穩定性指示測定。光譜快報, 1999, 32(6): 1073-1098。

[45] AHMAD I., ARSALAN A., SHERAZ M.A., AHMED S., ANWAR Z. 和 MUNIR I. 脂質體製劑中核黃素的配製和穩定性。光化學與光生物學雜誌乙: 生物學, 2015, 153: 358-366。

[46] LARINA L. 和 LOPYREV V. 硝唑類: 合成、結構和應用。第一版。斯普林格, 多德雷赫特, 海德堡, 倫敦, 2009年。

[47] MASOUD M., ELSAMRA R.M.I. 和 HEMDAN S. 溶劑、取代基和酸鹼度值對某些高色指示劑光譜偏移的影響。塞爾維亞化學學會雜誌, 2017, 82: 32-32。

[48] AHMAD I., ARSALAN A., ALI S.A., BANO R.,

MUNIR I. 和 SABAH A. 諾氟沙星在脂質體製劑中的配製和穩定性。歐洲藥學雜誌, 2016 年, 91: 208-215。

[49] LARINA L.I. 和 LOPYREV V.A. 硝基苯並唑的合成。第 1 部分。在: ATANASI O.A. 和 SPINELLI D. (編輯) 中。雜環系統中的目標-化學和性質。意大利社會化學: 意大利羅馬, 2005 年, 第 9 期, 第 327-365 頁。

[50] AHMAD I.、ABBAS S.H.、ANWAR Z.、SHERAZ M.A.、AHMED S.、ARSALAN A. 和 BANO R. 核黃素測定的穩定性指示光化學方法: 熒光法。化學雜誌, 2015 年, 文章編號 256087。

[51] AHMAD I.、ANWAR Z.、IQBAL K.、ALI S.A.、MIRZA T.、ADEELA A.A.、KHURSHID A. 和 ARSALAN A. 醋酸鹽和碳酸鹽緩衝液對水溶液中核黃素光解的影響: 動力學學習。美國藥學科學家協會 藥物科學技術, 2014, 15(3): 550-559

[52] DARWISH K.M.、SALAMA I.、MOSTAFA S. 和 EL-SADEK M. 使用溴百里酚藍染料通過酸性染料絡合對甲硝唑、替硝唑、奧硝唑和塞克硝唑鹼進行萃取分光光度分析。巴基斯坦藥學雜誌, 2012, 25(1): 207-217。

[53] SINGH A.、PATHAK D. 和 PATHAK K. 使用微孔阿克瑞爾國會議員 1000 十二指腸遞送塞克硝唑: 一種高劑量、胃酸鹼度值不穩定的藥物。國際藥物輸送技術雜誌, 2010, 2 (2): 26-34。

[54] 藥物的未來。藥物標準數據庫。藥典。https://www.drugfuture.com/Pharmacopoeia/USP32/pub/dat/v32270/usp32nf27s0_alpha-2-12.html (2022 年 1 月 17 日訪問)

[55] AHMAD I.、ANWAR Z.、AHMED S.、SHERAZ M.A.、BANO R. 和 HAFEZ A. 溶劑對核黃素光解的影響。美國藥學科學家協會 醫藥科技, 2015 年, 16(5): 1122-1128。

[56] DANTAS M.G.B.、REIS S.A.G.B.、DAMASCENO C.M.D.、ROLIM L.A.、ROLIM-NETO P.J.、CARVALHO F.O.、QUINTANS-JUNIOR L.J. 和 DA SILVA ALMEIDA J.R.G. 含有單萜龍腦的凝膠製劑的開發和穩定性評估。科學世界雜誌, 2016 年: 文章 ID 7394685

[57] HINKS M.L.、BRADY M.V.、LIGNELL H.、SONG M.、GRAYSON J.W.、BERTRAM A.K.、LIN P.、LASKIN A.、LASKIN J. 和 NIZKORODOV S.A. 粘度對複雜二次有機氣溶膠材料光降解速率的影響。物理化學化學物理, 2016, 18(13): 8785-8793。

[58] LAIDLER K.J. 化學動力學中使用的術語表, 包括反應動力學 (國際理論與應用化學聯合會建議 1996)。理論與應用化學, 1996, 68(1): 149-192。

[59] GRISSOM C.B.、CHAGOVETZ A.M. 和 WANG Z. 使用增粘劑穩定維生素 B12 溶液以防止光解。藥學雜誌, 1993, 82 (6): 641-643。

[60] JERZYKIEWICZ M.、CWIELAG I. 和 JERZYKIEWICZ W. 生物柴油生產中粗甘油餾分的抗氧化和防腐性能。化工與生物技術學報, 2009, 84(8): 1196-1201。

[61] CAIRNS W.L. 和 METZLER D.E. 黃素的光化學降解。六。一種新的光產物及其在光解機理研究中的應用。美國化學學會雜誌, 1971 年, 93(11): 2772-2777。

[62] AHMAD I.、AHMED S.、ANWAR Z.、SHERAZ M.A. 和 SIKORSK M. 藥物和藥物產品的光穩定性和光穩

定性。國際光能雜誌, 2016 年: 文章 ID 8135608。

[63] VALLEJO J.J.、MESA M. 和 GALLARDO C. 評估化妝品配方中使用的溶劑中的阿伏苯宗光穩定性。簡歷, 2011, 18(1): 63-71。

[64] DOS SANTOS POLITI J.R.、DE MATOS P.R. 和 SALES M.J. 用作潤滑劑基礎的植物油的氧化和熱穩定性的比較研究。熱分析與量熱學報, 2013, 111(2): 1437-1442。

[65] MAO Y.、CHEN X.、XU B.、SHEN Y.、YE Z.、CHAURASIYA B.、LIU L.、LI Y.、XING X. 和 CHEN D. 依立諾克丁納米乳膠用於抗內寄生蟲的透皮給藥和外寄生蟲: 製備、體外和體內評估。藥物輸送, 2019, 26(1): 1104-1114。

[66] BAERTSCHI S.W.、CLAPHAM D.、FOTI C.、KLEINMAN M.H.、KRISTENSEN S.、REED R.A.、TEMPLETON A.C. 和 TONNESEN H.H. 使用中光穩定性的影響: 光穩定性測試和標籤的擬議指南以支持光敏劑的管理 醫藥產品, 第 2 部分: 局部用藥產品。藥學雜誌, 2015, 104(9): 2688-2701。

[67] BAJAJ H.、BISHT S.、YADAV M.、SINGH V. 和 SINGH M. 負載奈韋拉平的不含表面活性劑的殼聚糖微乳劑的設計和開發。波蘭藥學報, 2011, 68(6): 981-988。

[68] KRISTENSEN S. 生物活性化合物的光反應性。十七。溶劑相互作用對伯氨嗪的光譜性質和光穩定性的影響。製藥公司。2005, 60(6): 426-433。

[69] BRISAERT M. 和 PLAIZIER-VERCAMMEN J.A. 乳霜中維甲酸的光穩定性研究。國際藥劑學雜誌, 2007, 334(1-2): 56-61。

[70] YEBOAH A.、YING S.、LU J.、XIE Y.、AMOANIMAA-DEDE H.、BOATENG K.G.A.、CHEN M. 和 YIN X. 蓖麻油 (普通刻度線): 化學成分和理化性質綜述。食品科學與技術學報, 2021, 41(補充 2): 399-413。